Poxel S.A. (EPA:POXEL)
France
· Delayed Price · Currency is EUR 0.7120
+0.2000 (39.06%)
May 29, 2025, 5:38 PM CET
Poxel Revenue
Poxel had revenue of 1.16M EUR in the half year ending June 30, 2024, with 1,300.00% growth. This brings the company's revenue in the last twelve months to 2.19M, up 41.53% year-over-year. In the year 2023, Poxel had annual revenue of 1.98M with 193.92% growth.
Revenue (ttm)
2.19M
Revenue Growth
+41.53%
P/S Ratio
17.47
Revenue / Employee
364.67K
Employees
6
Market Cap
38.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.98M | 1.31M | 193.92% |
| Dec 31, 2022 | 674.00K | -12.72M | -94.97% |
| Dec 31, 2021 | 13.40M | 6.59M | 96.84% |
| Dec 31, 2020 | 6.81M | -19.75M | -74.37% |
| Dec 31, 2019 | 26.56M | -35.82M | -57.43% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 26.51B |
| Sanofi | 45.17B |
| Sartorius Stedim Biotech | 2.86B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 6.95B |
| Ipsen | 3.57B |
| Virbac | 1.40B |
| emeis Société anonyme | 5.64B |
Poxel News
- 1 day ago - New Clinical and Scientific Data on TWYMEEG® to be Presented at the 68th Annual Meeting of the Japan Diabetes Society - Benzinga
- 3 days ago - Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025 - Business Wire
- 16 days ago - Poxel S.A. reports Q1 results - Seeking Alpha
- 16 days ago - Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update - Business Wire
- 2 months ago - Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy - Business Wire
- 4 months ago - Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan - Business Wire
- 7 months ago - Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents - Business Wire
- 8 months ago - Poxel SA (STU:7PO) Full Year 2023 Earnings Call Highlights: Strategic Moves and Financial Challenges - GuruFocus